Wire · regulatory
FTC seeks contempt ruling against Martin Shkreli
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 October 2026 · Fusion42 review
The Federal Trade Commission and seven states are asking a federal judge to hold Martin Shkreli in contempt for allegedly violating a 2022 court order that banned him from the pharmaceutical industry. They seek forced divestment of his pharma stocks, repayment of profits with interest, escalating penalties for future breaches, and potential jail time.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 13 Oct 2026 and 14 Oct 2026.
◆ ◆ The Wire takeaway
You face fresh risks in pharma investing as the FTC pushes to enforce lifetime bans with harsh penalties. Expect closer scrutiny on ownership and trading for banned individuals' assets and factor it into your risk and compliance planning.
◆ Coverage
8 sources · first reported 13 Oct 2026 · latest 14 Oct 2026
◆ Topics